Philippe Moreau

Centre National de la Recherche Scientifique — France

Medicine · Health Sciences

159h-index106.5kcitations2.3kworks7.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(1433), Protein Degradation and Inhibitors(589), Peptidase Inhibition and Analysis(356), Cancer Treatment and Pharmacology(278), Chronic Lymphocytic Leukemia Research(198)

Publications2.2k total

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load
Blood·2025· 1 citedOpen Access
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study
Journal of Clinical Oncology·2025Open Access
Mise en place et visées d’un groupe Balint en rhumatologie
Revue du Rhumatisme·2025
European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025Open Access
NOIAA révélant une amylose AL systémique avec atteinte artérielle céphalique
La Revue de Médecine Interne·2025
Table S4 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
Figure S1 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
Figure S2 from Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
2025Open Access
Return to employment outcomes in patients with multiple myeloma
British Journal of Haematology·2025
Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study
Blood·2025Open Access
Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients
Blood·2025· 1 citedOpen Access
First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.
Blood·2025
Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry
Blood·2025Open Access
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
HemaSphere·2025· 1 citedOpen Access
Preemptive Immunoglobulin Prophylaxis Reduces Infections in Patients Treated With Anti-BCMA Bispecific Antibodies
Clinical Lymphoma Myeloma & Leukemia·2025Open Access
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)
JMIR Formative Research·2025Open Access
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
Blood Cancer Journal·2025· 1 citedOpen Access
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
Blood·2025· 4 citedOpen Access
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
The Lancet Oncology·2025· 5 citedOpen Access
European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
HemaSphere·2025· 2 citedOpen Access
page 1 of 111Next →

Frequent Co-authors

Jesús F. San Miguel(24), Meletios Α. Dimopoulos(22), Thierry Façon(21), Paul G. Richardson(20), Hervé Avet‐Loiseau(19), Hartmut Goldschmidt(18), Michel Attal(18), Michèle Cavo(17), Kenneth C. Anderson(15), Xavier Leleu(15), Hermann Einsele(14), Sagar Lonial(13), Robert Z. Orlowski(13), Pieter Sonneveld(13), Antonio Palumbo(12), Shaji Kumar(10), Brian G.M. Durie(10), S. Vincent Rajkumar(10), Heinz Ludwig(9), Albert Oriol(9)